NeoGenomics launched PTEN IHC CDx, the first IHC companion diagnostic test approved by the U.S. FDA for patients with prostate adenocarcinoma.
Functional Characterization and a Real-World Clinical Laboratory Pilot of the Foundation for the National Institutes of Health Circulating Tumor DNA Quality Control Materials A total of 871 patient ...
BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test offerings to ...
Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine ...
CAI, has introduced in-house PTEN immunohistochemistry testing. The launch follows FDA approval of a biomarker guided therapy for PTEN deficient metastatic prostate cancer. The new PTEN IHC service is ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification ...
While receiving a metastatic cancer diagnosis can be overwhelming, it is important to keep in mind that not all cancers are the same. Knowing what makes your cancer unique and understanding treatment ...
FORT MYERS, Fla., July 09, 2026--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of ...
Available within NEO PanTracer™ Pro for prostate cancer and as a standalone test, PTEN IHC CDx identifies patients who may be eligible for TRUQAP® NeoGenomics, Inc. (NASDAQ: NEO), a leading provider ...
NeoGenomics, Inc.(NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PTEN IHC CDx, the first immunohistochemistry (IHC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results